Literature DB >> 11724154

Interim guidelines for investigation of and response to Bacillus anthracis exposures.

.   

Abstract

Environmental Sampling. Environmental testing to detect B. anthracis on surfaces or in the air can be used to investigate known or suspected exposure events. The highest priority of an investigation is to evaluate the risk for exposure to aerosolized B. anthracis spores. Persons collecting and testing samples should 1) obtain adequate samples, 2) avoid cross-contamination during processing, and 3) ensure proficient laboratory testing and interpretation of test results. A positive laboratory test for B. anthracis from a sample of an environmental surface may be caused by cross-contamination from an exposure vehicle (e.g., contact with an envelope containing B. anthracis), background occurrence of B. anthracis spores in the environment, or previously aerosolized B. anthracis that has settled onto environmental surfaces. Laboratory test results of environmental surface samples should not be the only criterion for starting, continuing, or stopping antimicrobial prophylaxis for inhalational disease.

Entities:  

Mesh:

Year:  2001        PMID: 11724154

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  15 in total

1.  In their own words: lessons learned from those exposed to anthrax.

Authors:  Janice C Blanchard; Yolanda Haywood; Bradley D Stein; Terri L Tanielian; Michael Stoto; Nicole Lurie
Journal:  Am J Public Health       Date:  2005-03       Impact factor: 9.308

2.  The anthrax vaccine and research: reactions from postal workers and public health professionals.

Authors:  Sandra Crouse Quinn; Tammy Thomas; Supriya Kumar
Journal:  Biosecur Bioterror       Date:  2008-12

3.  PCR assay to detect Bacillus anthracis spores in heat-treated specimens.

Authors:  A Fasanella; S Losito; R Adone; F Ciuchini; T Trotta; S A Altamura; D Chiocco; G Ippolito
Journal:  J Clin Microbiol       Date:  2003-02       Impact factor: 5.948

4.  Clinical issues in the prophylaxis, diagnosis, and treatment of anthrax.

Authors:  David M Bell; Phyllis E Kozarsky; David S Stephens
Journal:  Emerg Infect Dis       Date:  2002-02       Impact factor: 6.883

5.  Anthrax postexposure prophylaxis in postal workers, Connecticut, 2001.

Authors:  Jennifer L Williams; Stephanie S Noviello; Kevin S Griffith; Heather Wurtzel; Jennifer Hamborsky; Joseph F Perz; Ian T Williams; James L Hadler; David L Swerdlow; Renee Ridzon
Journal:  Emerg Infect Dis       Date:  2002-10       Impact factor: 6.883

6.  Bioterrorism-related anthrax: international response by the Centers for Disease Control and Prevention.

Authors:  Christina S Polyak; Jonathan T Macy; Margarita Irizarry-De La Cruz; James E Lai; Jay F McAuliffe; Tanja Popovic; Segaran P Pillai; Eric D Mintz
Journal:  Emerg Infect Dis       Date:  2002-10       Impact factor: 6.883

7.  Antimicrobial postexposure prophylaxis for anthrax: adverse events and adherence.

Authors:  Colin W Shepard; Montse Soriano-Gabarro; Elizabeth R Zell; James Hayslett; Susan Lukacs; Susan Goldstein; Stephanie Factor; Joshua Jones; Renee Ridzon; Ian Williams; Nancy Rosenstein
Journal:  Emerg Infect Dis       Date:  2002-10       Impact factor: 6.883

8.  Investigation of bioterrorism-related anthrax, United States, 2001: epidemiologic findings.

Authors:  Daniel B Jernigan; Pratima L Raghunathan; Beth P Bell; Ross Brechner; Eddy A Bresnitz; Jay C Butler; Marty Cetron; Mitch Cohen; Timothy Doyle; Marc Fischer; Carolyn Greene; Kevin S Griffith; Jeannette Guarner; James L Hadler; James A Hayslett; Richard Meyer; Lyle R Petersen; Michael Phillips; Robert Pinner; Tanja Popovic; Conrad P Quinn; Jennita Reefhuis; Dori Reissman; Nancy Rosenstein; Anne Schuchat; Wun-Ju Shieh; Larry Siegal; David L Swerdlow; Fred C Tenover; Marc Traeger; John W Ward; Isaac Weisfuse; Steven Wiersma; Kevin Yeskey; Sherif Zaki; David A Ashford; Bradley A Perkins; Steve Ostroff; James Hughes; David Fleming; Jeffrey P Koplan; Julie L Gerberding
Journal:  Emerg Infect Dis       Date:  2002-10       Impact factor: 6.883

9.  Epidemiologic response to anthrax outbreaks: field investigations, 1950-2001.

Authors:  Michael E Bales; Andrew L Dannenberg; Philip S Brachman; Arnold F Kaufmann; Peter C Klatsky; David A Ashford
Journal:  Emerg Infect Dis       Date:  2002-10       Impact factor: 6.883

10.  Public health in the time of bioterrorism.

Authors:  Bradley A Perkins; Tanja Popovic; Kevin Yeskey
Journal:  Emerg Infect Dis       Date:  2002-10       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.